CoChat

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Open access
van Zeventer, Isabelle A., Salzbrunn, Jonas B., de Graaf, Aniek O., van der Reijden, Bert A., Boezen, H. Marike, Vonk, Judith M., van der Harst, Pim, Schuringa, Jan Jacob, Jansen, Joop H., Huls, Gerwin · 2021 · Blood Advances
Cited by 83

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Clonal hematopoiesis (CH), characterized by a fraction of peripheral blood cells carrying an acquired genetic variant, emerges with age. Although in general CH is associated with increased mortality and morbidity, no higher risk of death was observed for individuals ≥80 years. Here, we investigated CH in 621 individuals aged ≥80 years from the population-based LifeLines cohort. Sensitive error-corrected sequencing of 27 driver genes at a variant allele frequency ≥1% revealed CH in the majority (62%) of individuals, independent of gender. The observed mutational spectrum was dominated by DNMT3A and TET2 variants, which frequently (29%) displayed multiple mutations per gene. In line with previous results in individuals ≥80 years, the overall presence of CH did not associate with a higher risk of death (hazard ratio, 0.91; 95% confidence interval, 0.70-1.18; P = .48). Being able to assess the causes of death, we observed no difference between individuals with or without CH, except for deaths related to hematological malignancies. Interestingly, comparison of mutational spectra confined to DNMT3A and TET2 vs spectra containing other mutated genes, showed a higher risk of death when mutations other than DNMT3A or TET2 were present (hazard ratio, 1.48; 95% confidence interval, 1.06-2.08; P = .025). Surprisingly, no association of CH with cardiovascular morbidity was found, irrespective of clone size. Further, CH associated with chronic obstructive pulmonary disease. Data on estimated exposure to DNA damaging toxicities (ie, smoking, a history of cancer [as a proxy for previous genotoxic therapy], and job-related pesticide exposure) showed an association with spliceosome and ASXL1 variants, but not with DNMT3A and TET2 variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020004062

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 83

Metadata

Authors
van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G.
Venue
Blood Advances
Published
2021-04-20
Volume
5
Issue
8
Pages
2115-2122
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3155628987
Cited by
83
References
13
FWCI
7.49
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. https://app.cochat.ai/papers/10.1182/bloodadvances.2020004062
The paper
van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G. (2021). Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. Blood Advances. https://doi.org/10.1182/bloodadvances.2020004062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.